Track Molecular Partners AG's EBIT ($-56M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowAs of Sep 30, 2026
Trailing 12 months ending Sep 30, 2026
Molecular Partners AG (MLLCF) currently reports a EBIT of $-56M as of September 2026. That compares with $-60M in the prior-year period — up 7.4% year over year. That is below the Healthcare sector average of $1.9T. Use the charts on this page to explore Molecular Partners AG's EBIT history and peer comparisons.
Molecular Partners AG's EBIT increased from $-60M to $-56M — a 7.4% year-over-year increase (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Molecular Partners AG's EBIT of $-56M is lower than the Healthcare sector average of $1.9T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
Molecular Partners AG reported $-56M in EBIT as of September 2026. That compares with $-60M in the prior-year period — up 7.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current EBIT of $-56M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $1.9T. From there, open related valuation or income-statement pages for Molecular Partners AG, and consider following MLLCF for alerts when major investors trade the stock.